Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis - Scorecard - MDSpire

Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis

  • By

  • Mariusz Ciołkiewicz

  • Anna Kuryliszyn-Moskal

  • Ewa Jabłońska

  • Wioletta Ratajczak-Wrona

  • Jacek Janica

  • Włodzimierz Samborski

  • Piotr A. Klimiuk

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Association of Liver Steatosis, Specific Organokines, and Cardiovascular Risk Factors in Patients with Rheumatoid Arthritis

At a Glance

CategoryDetail
Condition
Key MechanismsAssociation with cardiovascular morbidity, systemic inflammation, and liver-derived signaling molecules (hepatokines) - ensure this is directly sourced.
Target Population
Care Setting

Key Highlights

  • Remove unsupported conclusions or implications.

Guideline-Based Recommendations

Diagnosis

    Management

    • Ensure monitoring recommendations are directly supported by the source.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Clarify that further investigation of organokines is suggested by the study, not an editorial conclusion.

        Clinical Best Practices

        • Remove any practices not directly supported by the source material.

        Related Resources & Content

        Original Source(s)

        Related Content